BioDue S.p.A.

BIO2

IT0005108730

Pharmaceuticals

Delayed Borsa Italiana Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-.--%

2023	The Riverside Company acquired a controlling stake in BioDue S.p.A from Armònia.	CI
2022	The Riverside Company signed a definitive agreement to acquire a controlling stake in BioDue S.p.A from Arm=nia.	CI

Aurora Dodici S.p.A. made an tender offer to acquire 16.16% stake in BioDue S.p.A. (BIT : BIO2) for €11.7 million.

October 30, 2019

Aurora Dodici S.p.A. made an tender offer to acquire 16.16% stake in BioDue S.p.A. (BIT:BIO2) for €11.7 million on October 30, 2019. Under the agreement, Aurora Dodici S.p.A. will acquire 1.8 million shares of of BioDue S.p.A. for €6.5 per share.

Latest news about BioDue S.p.A.

The Riverside Company acquired a controlling stake in BioDue S.p.A from Armònia.	23-01-15	CI
The Riverside Company signed a definitive agreement to acquire a controlling stake in BioDue S.p.A from Arm=nia.	22-11-15	CI
Labomar S.p.A. acquired remaining 51.2% stake in LaBiotre S.r.l. from BioDue S.p.A. for €8.4 million.	21-11-22	CI
Aurora Dodici S.p.A. completed the acquisition of 12.1% stake in BioDue S.p.A. (BIT : BIO2) for €8.8 million.	19-11-28	CI
Aurora Dodici S.p.A. made an tender offer to acquire 16.16% stake in BioDue S.p.A. (BIT : BIO2) for €11.7 million.	19-10-30	CI
Armonia SGR SPA and the Rovati family signed a preliminary agreement to acquire 48.6% stake in BioDue S.p.A. from Vanni Benedetti, Ruffo Benedetti and Pierluigi Guasti for €35.2 million.	19-08-05	CI
BioDue, Fufarma to Build Drug Plant in Tirana	17-03-10	CI
BioDue S.p.A. has completed an IPO in the amount of €4 million.	15-05-19	CI
BioDue S.p.A. has filed an IPO.	15-05-15	CI

Chart BioDue S.p.A.

Duration

Period

More charts

Company Profile

BioDue SpA is an Italy-based consolidated industrial and commercial enterprise oriented towards the research, development, production and commercialization of cosmetic products, medical devices and food supplements, both liquid and solid. It manages almost its entire supply chain from raw materials to the research and development of formulations, right up to the production and relative commercialization of products throughout the world. The Company is structured around two divisions with specific competencies: Contract Manufacturing and Brand Owner. Contract Manufacturing is entirely dedicated to the manufacture of third party brand solid and liquid food supplements, cosmetics and medical devices. Brand Owner manufactures and commercializes own-brand dermatological, ophthalmic products and food supplements under the brands Pharcos, Biofta, Selerbe.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BIODUE S.P.A.	-.--%	80.72M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals

BioDue S.p.A.

Equities

BIO2

IT0005108730

Pharmaceuticals

Aurora Dodici S.p.A. made an tender offer to acquire 16.16% stake in BioDue S.p.A. (BIT : BIO2) for €11.7 million.

Latest news about BioDue S.p.A.

Chart BioDue S.p.A.

Company Profile

Sector Other Pharmaceuticals